MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock in...
$3,808,439
Proceeds from warrant
inducement, net of issuance...
$2,480,553
Proceeds from 2025
january registered...
$2,099,253
Proceeds from warrant
exercise
$1,360,544
Proceeds from 2025 march
registered direct...
$889,420
Net cash provided by
financing activities
$10,637,169
Canceled cashflow
$1,040
Net
increase/(decrease) in cash
$3,849,387
Canceled cashflow
$6,787,782
Reverse stock split
fractional share...
$1,040
Share-based compensation
$1,247,401
Share-based payments to
vendors
$322,319
Prepaid expenses
-$15,105
Other receivable
-$2,710
Net cash used in
operating activities
-$6,787,782
Canceled cashflow
$1,587,535
Net loss
-$7,966,538
Accounts payable and
accrued expenses
-$408,779
Back
Back
Cash Flow
source: myfinsight.com
Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc. (ACXP)